AGP Picks
View all

Connecticut Health Digest
Provided by AGP

Connecticut Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Connecticut Health Digest.

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

Press releases published on June 8, 2026

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Jun. 8, 2026

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Indeterminate GlobeNewswire
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
Jun. 8, 2026

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Indeterminate GlobeNewswire
[Latest] Surgical Masks Market Size Will Attain USD 6.76 Billion by 2034 Registering a Promising CAGR of 5.5% - Exclusive Report by ZMR | Global Surgical Masks Market Size, Share, Trends Analysis Report
Jun. 8, 2026

[Latest] Surgical Masks Market Size Will Attain USD 6.76 Billion by 2034 Registering a Promising CAGR of 5.5% - Exclusive Report by ZMR | Global Surgical Masks Market Size, Share, Trends Analysis Report

Indeterminate GlobeNewswire
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Jun. 8, 2026

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Indeterminate GlobeNewswire
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Jun. 8, 2026

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Indeterminate GlobeNewswire
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
Jun. 8, 2026

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

Indeterminate GlobeNewswire
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Jun. 8, 2026

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Indeterminate GlobeNewswire
Shattuck Labs Announces Phase 1 Results for SL-325
Jun. 8, 2026

Shattuck Labs Announces Phase 1 Results for SL-325

Indeterminate GlobeNewswire
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 
Jun. 8, 2026

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion 

Indeterminate GlobeNewswire
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Jun. 8, 2026

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Indeterminate GlobeNewswire
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
Jun. 8, 2026

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Indeterminate GlobeNewswire
Intravacc stellt integrierte analytische Kompetenzen zur Beschleunigung der Entwicklung von Impfstoffen und Biologika vor
Jun. 8, 2026

Intravacc stellt integrierte analytische Kompetenzen zur Beschleunigung der Entwicklung von Impfstoffen und Biologika vor

Indeterminate GlobeNewswire
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
Jun. 8, 2026

Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development

Indeterminate GlobeNewswire
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Jun. 8, 2026

Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia

Indeterminate GlobeNewswire
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
Jun. 8, 2026

Reminder: Nicox June 2024 Warrants will expire June 19, 2026

Indeterminate GlobeNewswire
Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
Jun. 8, 2026

Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026

Indeterminate GlobeNewswire
Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable
Jun. 8, 2026

Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable

Indeterminate GlobeNewswire
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Jun. 8, 2026

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Connecticut Health Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.